A61K 40/4231
Cytokines
Official title: {Cytokines}
A61K40/4231 (Cytokines) appears on 157 US grants and 438 published applications in this corpus.
Search patents in A61K- Granted patents
- 157
- Published applications
- 438
- Assignees
- 205
- Inventors
- 925
- Latest grant
- 22 Sep 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1992 | 1 | 0 |
| 1993 | 0 | 0 |
| 1994 | 0 | 0 |
| 1995 | 1 | 0 |
| 1996 | 1 | 0 |
| 1997 | 0 | 0 |
| 1998 | 0 | 0 |
| 1999 | 0 | 0 |
| 2000 | 0 | 0 |
| 2001 | 0 | 0 |
| 2002 | 0 | 5 |
| 2003 | 0 | 5 |
| 2004 | 0 | 6 |
| 2005 | 0 | 4 |
| 2006 | 3 | 4 |
| 2007 | 1 | 3 |
| 2008 | 6 | 3 |
| 2009 | 2 | 5 |
| 2010 | 2 | 2 |
| 2011 | 1 | 5 |
| 2012 | 2 | 5 |
| 2013 | 3 | 4 |
| 2014 | 4 | 6 |
| 2015 | 3 | 1 |
| 2016 | 4 | 7 |
| 2017 | 2 | 6 |
| 2018 | 5 | 17 |
| 2019 | 4 | 18 |
| 2020 | 10 | 25 |
| 2021 | 15 | 44 |
| 2022 | 15 | 46 |
| 2023 | 17 | 47 |
| 2024 | 16 | 66 |
| 2025 | 20 | 66 |
| 2026 | 19 | 38 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Subgroups
Granted patents
Recent patents
- Methods for manufacturing genetically engineered CAR-T cells22 Sep 2026US 12,742,184 B2Crispr Therapeutics AG
- Combination immunotherapy15 Sep 2026US 12,735,466 B2The Regents of the University of California
- Antigen-binding protein targeting CD70 and use thereof1 Sep 2026US 12,721,893 B2
- Methods of manufacturing CAR-T cells1 Sep 2026US 12,723,268 B2Crispr Therapeutics AG
- Cell immunotherapy for the treatment of cancer14 Jul 2026US 12,678,486 B2Board of Regents, The University of Texas System
- Car-t cells co-expressing cd40l1 Oct 2026US 2026/0294969 A1H. Lee Moffitt Cancer Center and Research Institute, Inc.
- Cell immunotherapy for the treatment of cancer1 Oct 2026US 2026/0295011 A1Board of Regents, The University of Texas System
- Switch receptors1 Oct 2026US 2026/0295042 A1Hoffmann-La Roche Inc.
- CD70 CAR-T Compositions and Methods for Cell-based Therapy24 Sep 2026US 2026/0285995 A1Intellia Therapeutics, Inc.
- Media and methods for differentiating t cells from hematopoietic stem cells17 Sep 2026US 2026/0272984 A1The Regents of the University of California
Most cited
By later US patents
- Gene therapy759US 5,399,346 AThe United States of America as represented by the Department of Health and Human Services · 1995
- Method and compositions using a chimeric antigen receptor for enhanced anti-tumor effector functioning of T cells121US 8,822,647 B2City of Hope · 2014
- Chimeric immunoreceptor useful in treating human gliomas101US 8,324,353 B2City of Hope · 2012
- Chimeric immunoreceptor useful in treating human cancers68US 8,497,118 B2City of Hope · 2013
- Method of inducing memory B cell development and terminal differentiation33US 7,378,276 B2The United States of America as represented by the Department of Health and Human Services · 2008